Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Kee

Showing results (31-40 of 51) with videos related to

Pageof 6
Sort By:
Oncotarget|April 21, 2017
FBXW7 missense mutation: a novel negative prognostic factor in metastatic colorectal adenocarcinomaKrittiya Korphaisarn, Van Karlyle Morris, Michael J Overman, et al.
QJM : Monthly Journal of the Association of Physicians|March 20, 2018
Microscopic hematuria is a risk factor of incident chronic kidney disease in the Korean general population: a community-based prospective cohort studyH Kim, M Lee, M-U Cha, et al.
Medicine|November 3, 2017
Prevalence of depression and suicidal ideation increases proportionally with renal function decline, beginning from early stages of chronic kidney diseaseJong H Jhee, Eun Lee, Min-Uk Cha, et al.
British Journal of Cancer|August 14, 2019
Signet ring cell colorectal cancer: genomic insights into a rare subpopulation of colorectal adenocarcinomaKrittiya Korphaisarn, Van Morris, Jenifer S Davis, et al.
JCO Precision Oncology|October 12, 2023
Novel Clinical Tool to Estimate Risk of False-Negative KRAS Mutations in Circulating Tumor DNA TestingStefania Napolitano, Aparna R Parikh, Jason Henry, et al.
Cancer Chemotherapy and Pharmacology|June 14, 2023
A phase I trial of the pan-ERBB inhibitor neratinib combined with the MEK inhibitor trametinib in patients with advanced cancer with EGFR mutation/amplification, HER2 mutation/amplification, HER3/4 mutation or KRAS mutationSarina A Piha-Paul, Chieh Tseng, Hai T Tran, et al.
Hong Kong Medical Journal = Xianggang Yi Xue Za Zhi|December 8, 2010
Rapid aneuploidy screening with fluorescence in-situ hybridisation: is it a sufficiently robust stand-alone test for prenatal diagnosis?A S T Lim, T H Lim, M M Hess, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 29, 2015
Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatmentM P Morelli, M J Overman, A Dasari, et al.
Plos One|March 8, 2017
Association of SMAD4 mutation with patient demographics, tumor characteristics, and clinical outcomes in colorectal cancerAmir Mehrvarz Sarshekeh, Shailesh Advani, Michael J Overman, et al.
Cancer|November 23, 2017
Physician interpretation of genomic test results and treatment selectionLauren L Brusco, Chetna Wathoo, Kenna R Mills Shaw, et al.
Pageof 6

Showing results (31-40 of 51) with videos related to

Sort By:
Pageof 6
Oncotarget|April 21, 2017
FBXW7 missense mutation: a novel negative prognostic factor in metastatic colorectal adenocarcinomaKrittiya Korphaisarn, Van Karlyle Morris, Michael J Overman, et al.
QJM : Monthly Journal of the Association of Physicians|March 20, 2018
Microscopic hematuria is a risk factor of incident chronic kidney disease in the Korean general population: a community-based prospective cohort studyH Kim, M Lee, M-U Cha, et al.
Medicine|November 3, 2017
Prevalence of depression and suicidal ideation increases proportionally with renal function decline, beginning from early stages of chronic kidney diseaseJong H Jhee, Eun Lee, Min-Uk Cha, et al.
British Journal of Cancer|August 14, 2019
Signet ring cell colorectal cancer: genomic insights into a rare subpopulation of colorectal adenocarcinomaKrittiya Korphaisarn, Van Morris, Jenifer S Davis, et al.
JCO Precision Oncology|October 12, 2023
Novel Clinical Tool to Estimate Risk of False-Negative KRAS Mutations in Circulating Tumor DNA TestingStefania Napolitano, Aparna R Parikh, Jason Henry, et al.
Cancer Chemotherapy and Pharmacology|June 14, 2023
A phase I trial of the pan-ERBB inhibitor neratinib combined with the MEK inhibitor trametinib in patients with advanced cancer with EGFR mutation/amplification, HER2 mutation/amplification, HER3/4 mutation or KRAS mutationSarina A Piha-Paul, Chieh Tseng, Hai T Tran, et al.
Hong Kong Medical Journal = Xianggang Yi Xue Za Zhi|December 8, 2010
Rapid aneuploidy screening with fluorescence in-situ hybridisation: is it a sufficiently robust stand-alone test for prenatal diagnosis?A S T Lim, T H Lim, M M Hess, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 29, 2015
Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatmentM P Morelli, M J Overman, A Dasari, et al.
Plos One|March 8, 2017
Association of SMAD4 mutation with patient demographics, tumor characteristics, and clinical outcomes in colorectal cancerAmir Mehrvarz Sarshekeh, Shailesh Advani, Michael J Overman, et al.
Cancer|November 23, 2017
Physician interpretation of genomic test results and treatment selectionLauren L Brusco, Chetna Wathoo, Kenna R Mills Shaw, et al.
Pageof 6